- Home
- TARA vs ALEC Comparison
TARA vs ALEC Comparison
Compare TARA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | ALEC |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.9M | 245.4M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TARA | ALEC |
|---|---|---|
| Price | $4.78 | $2.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $24.40 | $4.83 |
| AVG Volume (30 Days) | ★ 727.9K | 544.9K |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,948,000.00 | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $29.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $1.09 |
| 52 Week High | $7.82 | $3.40 |
Technical Indicators
Market Signals| Indicator | TARA | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 43.73 |
| Support Level | $3.01 | $1.91 |
| Resistance Level | $5.53 | $2.64 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 30.29 | 18.71 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.